-
公开(公告)号：US11058715B2
公开(公告)日：2021-07-13
申请号：US15172209
申请日：2016-06-03
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K31/74 , A61K31/75 , A61K9/00 , A61K9/16 , A61K9/50 , B01J20/26 , B01J20/28 , B01J20/30 , C08F212/36 , C08J9/26 , A61K47/58
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
-
公开(公告)号：US11020521B2
公开(公告)日：2021-06-01
申请号：US16851305
申请日：2020-04-17
Applicant: CytoSorbents Corporation
Inventor： Thomas D. Golobish , Vincent J. Capponi , David R. Clay
Abstract: The invention concerns methods of removing undesirable molecules from the blood or physiologic fluid; said method comprising contacting said blood or physiologic fluid with a sorbent, said sorbent comprising a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of ligands attached to the surface of said cross-linked polymeric material, comprising (i) zwitterionic moieties, (ii) oligo(ethylene glycol) moieties or (iii) mixtures thereof; said contacting comprising said sorbent sorbing a plurality of said undesirable molecules when said sorbent is administered within a patient's body.
-
公开(公告)号：US20160279163A1
公开(公告)日：2016-09-29
申请号：US15172209
申请日：2016-06-03
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Robert H. Bartlett , Humayra Begum Ali
IPC: A61K31/745 , A61K9/00 , A61K47/48
CPC classification number: A61K31/745 , A61K9/0053 , A61K9/16 , A61K9/50 , A61K31/74 , A61K31/75 , A61K47/58 , B01J20/261 , B01J20/28004 , B01J20/28073 , B01J20/28076 , B01J20/3064 , C08F212/36 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2325/02 , Y02A50/406 , Y02A50/411
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
Abstract translation: 本发明涉及从患有或处于炎症风险的患者处理全身，局部或局部炎症的方法，其包括施用治疗有效剂量的吸附所述患者中的炎性介质的吸附剂。 在一些优选实施方案中，吸附剂是生物相容性有机聚合物。
-
公开(公告)号：US20150335576A1
公开(公告)日：2015-11-26
申请号：US14410901
申请日：2013-06-28
Applicant: Cytosorbents Corporation
Inventor： Phillip P. Chan , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
CPC classification number: A61M1/3679 , A61K9/16 , A61K31/765 , A61M2202/0057 , A61M2202/0405 , A61M2202/0413 , A61M2202/0415 , A61M2202/0423 , A61M2202/0464 , A61M2202/0466 , A61M2202/049 , A61M2202/0492 , A61M2202/0496 , A61M2202/20 , A61M2202/203 , A61M2202/206 , B01J20/261 , B01J20/28069 , B01J20/28078 , C08F299/00 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2353/00
Abstract: Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.
Abstract translation: 本文提供的是减少生物物质中的污染物或通过一种或多种毒素治疗受试者污染物的材料和方法，包括使生物物质与有效量的能够吸附毒素的吸附剂接触，其中吸附剂包括多个孔 范围从50埃到40,000埃，孔体积为0.5cc / g至5.0cc / g，尺寸为0.05mm至2cm，并吸附毒素。 还提供了用于减少包含能够吸附毒素的吸附剂的生物物质中的一种或多种毒素污染的试剂盒，其中所述吸附剂包括多孔孔径为50〜40,000埃，孔体积为0.5cc / g至 5.0cc / g和0.05mm至2cm的尺寸，以及当不与其一起使用的包装一起存储所述吸附剂的容器。
-
公开(公告)号：US20210330697A1
公开(公告)日：2021-10-28
申请号：US17229265
申请日：2021-04-13
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K31/74 , A61K31/75 , A61K9/00 , A61K9/16 , A61K9/50 , B01J20/26 , B01J20/28 , B01J20/30 , C08F212/36 , C08J9/26 , A61K47/58
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
-
Patent Agency Ranking
公开(公告)号：US20190282608A1
公开(公告)日：2019-09-19
申请号：US16424747
申请日：2019-05-29
Applicant: Cytosorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K47/58 , A61K31/75 , A61K9/00 , C08J9/26 , C08F212/36 , B01J20/28 , A61K9/16 , B01J20/26 , B01J20/30 , A61K31/74 , A61K9/50
Abstract: The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.
-
公开(公告)号：US10314859B2
公开(公告)日：2019-06-11
申请号：US15886978
申请日：2018-02-02
Applicant: Cytosorbents Corporation
Inventor： Humayra Begum Ali , Thomas D. Golobish , Vincent J. Capponi , Phillip P. Chan , Wei Tai Young , Andrew Robert Scheirer
IPC: A61M31/00 , A61K31/74 , A61K31/765 , A61P1/06 , A61P1/04 , A61P1/00 , A61K9/00 , A61K31/79 , A61K31/75
Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
-
公开(公告)号：US10034894B2
公开(公告)日：2018-07-31
申请号：US15635517
申请日：2017-06-28
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K9/16 , A61K9/50 , C08J9/26 , B01J20/26 , B01J20/30 , A61K9/00 , B01J20/28 , C08F212/36 , A61K31/74 , A61K31/75 , A61K47/58
CPC classification number: A61K31/745 , A61K9/0053 , A61K9/16 , A61K9/50 , A61K31/74 , A61K31/75 , A61K47/58 , B01J20/261 , B01J20/28004 , B01J20/28073 , B01J20/28076 , B01J20/3064 , C08F212/36 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2325/02 , Y02A50/406 , Y02A50/411
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
-
公开(公告)号：US20180169138A1
公开(公告)日：2018-06-21
申请号：US15886978
申请日：2018-02-02
Applicant: Cytosorbents Corporation
Inventor： Humayra Begum Ali , Thomas D. Golobish , Vincent J. Capponi , Phillip P. Chan , Wei Tai Young , Andrew Robert Scheirer
IPC: A61K31/765 , A61K9/00
CPC classification number: A61K31/765 , A61K9/0053 , A61K31/75 , A61K31/79 , A61P1/00 , A61P1/04 , A61P1/06
Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
-
公开(公告)号：US20170296574A1
公开(公告)日：2017-10-19
申请号：US15635517
申请日：2017-06-28
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K9/16 , A61K9/50 , C08J9/26 , B01J20/26 , B01J20/30 , A61K9/00 , B01J20/28 , C08F212/36
CPC classification number: A61K31/745 , A61K9/0053 , A61K9/16 , A61K9/50 , A61K31/74 , A61K31/75 , A61K47/58 , B01J20/261 , B01J20/28004 , B01J20/28073 , B01J20/28076 , B01J20/3064 , C08F212/36 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2325/02 , Y02A50/406 , Y02A50/411
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.022 seconds)
